- Record: found
- Abstract: found
- Article: found
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma.
Tadaaki Arizumi
1 ,
Kazuomi Ueshima
1 ,
Tomohiro Minami
1 ,
Masashi Kono
1 ,
Hirokazu Chishina
1 ,
Masahiro Takita
1 ,
Satoshi Kitai
1 ,
Tatsuo Inoue
1 ,
Norihisa Yada
1 ,
Satoru Hagiwara
1 ,
Yasunori Minami
1 ,
Toshiharu Sakurai
1 ,
Naoshi Nishida
1 ,
Masatoshi Kudo
1
Dec 2015
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Patients with intermediate-stage hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE) are considered to be candidates for sorafenib. The aim of this study was to evaluate the superiority of conversion of treatment to sorafenib on overall survival (OS) for cases refractory to TACE.